⏳ Fetching live dividend data...
Home › Calculator › ADMS Dividend Calculator 2026
Adamas Pharmaceuticals, Inc. · NASDAQ
Price: $8.22 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ADMS → $12.94M in 10 years · $256.11/month
Adamas Pharmaceuticals, Inc. is focused on the research, development, and commercialization of therapeutic solutions for individuals in the United States suffering from chronic neurological conditions. The company's marketed products include GOCOVRI, an extended-release capsule designed to treat dyskinesia in Parkinson's disease patients who are undergoing levodopa-based therapy, with or without other dopaminergic medications. Additionally, they provide Namzaric capsules, a combination of extended-release memantine hydrochloride and donepezil hydrochloride, used for managing moderate to severe Alzheimer's-type dementia. In its development pipeline, Adamas is progressing ADS-5102, which is currently undergoing Phase III clinical trials to address walking difficulties in patients with multiple sclerosis, among other potential applications. The firm has also completed two Phase I studies for ADS-4101, a candidate treatment for partial onset seizures in epilepsy patients. Founded in 2000, the company initially operated as NeuroMolecular Pharmaceuticals, Inc. before changing its name to Adamas Pharmaceuticals, Inc. in July 2007. Its corporate headquarters are located in Emeryville, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ADMS position with:
Real after-tax yield depends on where you live and how you hold ADMS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 24.33% | 21.53% | $2,433 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 20.68% | 17.88% | $2,068 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 19.46% | 16.66% | $1,946 / yr |
| 🇬🇧 UK ISA | 0% | 24.33% | 21.53% | $2,433 / yr |
| 🇬🇧 UK Taxable | 8.75% | 22.20% | 19.40% | $2,220 / yr |
| 🇨🇦 TFSA | 0% | 24.33% | 21.53% | $2,433 / yr |
| 🇨🇦 CA Taxable | 25% | 18.25% | 15.45% | $1,825 / yr |
| 🇦🇺 Super (pension) | 15% | 20.68% | 17.88% | $2,068 / yr |
| 🇦🇺 AU Taxable | 30% | 17.03% | 14.23% | $1,703 / yr |
| 🇩🇪 DE Taxable | 26.375% | 17.91% | 15.11% | $1,791 / yr |
| 🇫🇷 FR Taxable | 30% | 17.03% | 14.23% | $1,703 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ADMS pays quarterly — 4 times per year. Next ex-div: TBD.
How ADMS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ADMS sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2021-11-24 | 10,000 | $4.80 | $48.0K | ||
| D-Return | 2021-11-24 | 40,000 | $6.08 | $243.2K | ||
| D-Return | 2021-11-24 | 10,000 | $2.70 | $27.0K | ||
| U-Tender | 2021-11-24 | 112,781 | $8.10 | $913.5K | ||
| D-Return | 2021-11-24 | 10,000 | $5.21 | $52.1K | ||
| A-Award | 2021-11-24 | 75,000 | — | — | ||
| U-Tender | 2021-11-24 | 600,000 | $8.10 | $4.86M | ||
| D-Return | 2021-11-24 | 250,000 | $6.25 | $1.56M | ||
| D-Return | 2021-11-24 | 200,000 | $1.99 | $398.0K | ||
| A-Award | 2021-11-24 | 18,750 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ADMS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Adamas Pharmaceuticals, Inc. (ADMS) is currently trading at $8.22, trading near its 52-week high. The current dividend yield is 24.33% based on an annual payout of $2.00 per share.
Adamas Pharmaceuticals, Inc. (ADMS) is a healthcare stock currently trading at $8.22 with a dividend yield of 24.33%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →